Blood and marrow transplantation during the emerging COVID-19 pandemic: the Seattle approach - Top-Institutions - MDSpire

Blood and marrow transplantation during the emerging COVID-19 pandemic: the Seattle approach

  • By

  • Masumi Ueda Oshima

  • Brenda M. Sandmaier

  • Effie Petersdorf

  • Mary E. Flowers

  • Geoffrey R. Hill

  • Stephanie J. Lee

  • Frederick R. Appelbaum

  • Paul A. Carpenter

  • K. Scott Baker

  • Laura Connelly-Smith

  • Andrea McCool

  • Suni Elgar

  • Steven A. Pergam

  • Catherine Liu

  • F. Marc Stewart

  • Marco Mielcarek

  • September 26, 2020

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Fred Hutchinson Cancer Research Center / Seattle Cancer Care Alliance
    Fred Hutchinson Cancer Research Center / Seattle Cancer Care Alliance

    Seattle, WA

    Key Differentiators

    • Hematopoietic Stem Cell Transplantation
    • Infectious Diseases
    • Oncology

  • #2

    Dana-Farber Cancer Institute / Brigham and Women’s Hospital
    Dana-Farber Cancer Institute / Brigham and Women’s Hospital

    Boston, MA

    Key Differentiators

    • Hematopoietic Stem Cell Transplantation
    • Infectious Diseases
    • Hematology/Oncology

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematopoietic Stem Cell Transplantation
    • Oncology
    • Infectious Diseases

  • #4

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematopoietic Stem Cell Transplantation
    • Oncology
    • Infectious Diseases

Original Source(s)

Blood and marrow transplantation during the emerging COVID-19 pandemic: the Seattle approach

  • by Masumi Ueda Oshima, Brenda M. Sandmaier, Effie Petersdorf, Mary E. Flowers, Geoffrey R. Hill, Stephanie J. Lee, Frederick R. Appelbaum, Paul A. Carpenter, K. Scott Baker, Laura Connelly-Smith, Andrea McCool, Suni Elgar, Steven A. Pergam, Catherine Liu, F. Marc Stewart, Marco Mielcarek

  • September 26, 2020

Related Content

Equity and representation in oncology clinical evidence for FDA-approved treatments and the impact of COVID-19

Mendelian Randomization and Infection: Pitfalls and Promises

Improving outcomes with anti-BCMA bispecific antibodies with attention to infection